Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 42.84 USD 2.37% Market Closed
Market Cap: 2.9B USD
Have any thoughts about
Merus NV?
Write Note

Merus NV
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Merus NV
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Merus NV
NASDAQ:MRUS
Total Current Liabilities
$80.1m
CAGR 3-Years
4%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Total Current Liabilities
$79.8m
CAGR 3-Years
26%
CAGR 5-Years
-2%
CAGR 10-Years
20%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Current Liabilities
€39.6m
CAGR 3-Years
5%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Total Current Liabilities
$71.3m
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
18%
argenx SE
XBRU:ARGX
Total Current Liabilities
$499.6m
CAGR 3-Years
27%
CAGR 5-Years
37%
CAGR 10-Years
69%
LAVA Therapeutics NV
NASDAQ:LVTX
Total Current Liabilities
$14.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Merus NV
Glance View

Market Cap
2.9B USD
Industry
Biotechnology

Merus NV, a Dutch biotechnology company, stands at the forefront of innovative cancer therapies, channeling its efforts into research and development of multispecific antibodies. Its proprietary technology platform, Biclonics®, ingeniously harnesses the power of full-length human antibodies to target multiple pathways in the treatment of cancer. Each Biclonics® candidate is designed to bind simultaneously to more than one target, acting like a precision-guided missile that seeks out cancer cells and disrupts the signaling processes that allow tumors to grow and spread. This cutting-edge approach aims to overcome the limitations of traditional monoclonal antibodies and offers promising new avenues for tackling cancer’s incessant complexity. The company's business model is built upon a robust pipeline strategy, where promising drug candidates are both developed in-house and guided through strategic collaborations with larger pharmaceutical entities. These collaborations often involve licensing agreements that provide Merus NV with milestone payments and royalties, creating a significant revenue stream. As these partnerships amplify its reach and bolster its financial health, Merus maintains a primary focus on advancing its leading drug candidates through clinical trials. By aligning groundbreaking science with strategic collaborations, Merus NV works to convert its innovations into viable products that can potentially transform the landscape of cancer treatment, striving to turn scientific potential into practical solutions and profitable outcomes.

MRUS Intrinsic Value
24.64 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Merus NV's Total Current Liabilities?
Total Current Liabilities
80.1m USD

Based on the financial report for Sep 30, 2024, Merus NV's Total Current Liabilities amounts to 80.1m USD.

What is Merus NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
20%

Over the last year, the Total Current Liabilities growth was 25%. The average annual Total Current Liabilities growth rates for Merus NV have been 4% over the past three years , 20% over the past five years .

Back to Top